human
antiebov
zair
glycoprotein
gp
igg
titer
measur
use
commerci
avail
enzymelink
immunosorb
assay
elisa
kit
alpha
diagnost
intern
inc
follow
manufactur
protocol
optic
densiti
valu
nm
record
sampl
dilut
duplic
sampl
determin
mildli
reactiv
serum
antibodi
concentr
greater
unitsml
purifi
igg
control
calibr
sampl
consid
strongli
reactiv
harbor
titer
greater
unitsml
conserv
cutoff
use
previou
report
uml
cutoff
yield
sensit
specif
human
antiebov
zair
nucleoprotein
np
titer
measur
use
commerci
avail
elisa
kit
alpha
diagnost
intern
perform
san
francisco
ca
assay
perform
follow
manufactur
instruct
sampl
dilut
duplic
absorb
read
nm
sampl
determin
mildli
reactiv
serum
antibodi
concentr
greater
unitsml
control
calibr
strongli
reactiv
harbor
titer
greater
unitsml
ctermin
domain
mayinga
ebov
zair
viral
protein
bp
clone
plasmid
transfect
cell
gener
renilla
luciferas
antigen
fusion
protein
cell
lysat
harvest
use
immunoprecipit
assay
protein
ag
conjug
agaros
bead
describ
burbelo
et
al
final
step
bead
wash
time
buffer
time
phosphat
buffer
salin
use
vacuum
manifold
measur
luciferas
activ
use
renilla
luciferas
assay
system
substrat
promega
posit
determin
rel
luciferas
signal
postimmunoprecipit
least
standard
deviat
greater
background
signal
determin
averag
previous
identifi
neg
serum
sampl
posit
control
obtain
human
convalesc
patient
sera
collect
boend
drc
ebov
outbreak
data
present
rel
light
unit
rlu
patient
rlu
neg
control
valu
greater
consid
posit
pseudotyp
virus
gener
describ
previous
use
mayinga
zair
ebola
viru
glycoprotein
ebovgp
neg
control
vesicular
stomat
viru
glycoprotein
vsvg
express
plasmid
respect
pnlluc
viral
backbon
obtain
nih
aid
reagent
program
divis
aid
niaid
nih
catalog
pseudotyp
contain
cultur
supernat
pellet
sucros
cushion
ultracentrifug
hour
rpm
rotor
viral
pellet
resuspend
volum
hank
buffer
salin
solut
hbss
overnight
pseudotyp
viru
stock
aliquot
store
pseudotyp
virus
titer
human
rhabdomyosarcoma
rd
cell
determin
volum
requir
yield
rlu
luciferas
activ
cell
lysat
hour
postinfect
two
pseudotyp
viru
neutral
assay
perform
previous
describ
pseudotyp
viru
incub
serial
dilut
sera
infect
rd
cell
infect
complet
duplic
well
plate
contain
ident
control
includ
uninfect
cell
cell
infect
absenc
serum
cell
infect
presenc
neg
control
serum
us
donor
posit
control
serum
recent
confirm
ebola
survivor
infect
rate
presenc
human
serum
sampl
express
percentag
infect
presenc
neg
control
serum
determin
neutral
capabl
serum
patient
least
neutral
approxim
viru
compar
appropri
control
ebov
zairelik
particl
vlp
produc
use
prepar
previous
describ
use
gluciferas
gluc
complement
assay
entri
inhibit
vlp
incub
serial
dilut
sera
spininfect
target
cell
rd
cell
transient
express
glucc
duplic
gluc
activ
cell
lysat
measur
use
commerci
kit
pierc
accord
manufactur
instruct
express
percentag
luciferas
activ
presenc
neg
control
serum
plaqu
reduct
neutral
test
neutral
assay
live
viru
incub
presenc
serial
dilut
test
sampl
contain
condit
virussampl
mixtur
incub
cell
nonneutr
viru
infect
cell
monolay
antibodi
titer
calcul
compar
number
viru
plaqu
sampl
dilut
well
virusonli
control
well
test
sampl
sampl
serial
dilut
dulbecco
modifi
eagl
medium
dmem
rang
mix
ratio
isol
ebola
makona
either
complement
cedar
lane
lab
standard
guinea
pig
complement
media
incub
hour
follow
incub
virusserum
inoculum
ad
triplic
well
plate
contain
confluent
vero
cell
rock
everi
minut
hour
follow
incub
ml
overlay
avicel
minim
essenti
media
ad
well
incub
day
incub
overlay
remov
cell
monolay
fix
minut
room
temperatur
ml
crystal
violet
solut
neutralbuff
formalin
plate
wash
tap
water
dri
total
number
plaqu
form
unit
pfu
count
record
well
antiebola
viru
antibodi
ibt
bioservic
use
posit
control
assay
calcul
identifi
first
dilut
fewer
plaqu
compar
averag
number
plaqu
observ
virusonli
well
human
embryon
kidney
human
muscl
rd
african
green
monkey
cell
grown
dulbecco
modifi
essenti
medium
hyclon
supplement
fetal
bovin
serum
lglutamin
nonessenti
amino
acid
antibiot
penicillin
streptomycin
gibco
incub
assay
african
green
monkey
kidney
cell
vero
atcc
maintain
dmem
high
glucos
lglutamin
lonza
contain
heatinactiv
fetal
bovin
serum
sigma
life
scienc
cell
seed
one
day
prior
cellswel
plate
greiner
bioon
cellswel
plate
corn
respect
incub
univari
analysi
perform
categor
variabl
use
fisher
exact
test
appropri
use
sa
softwar
version
sa
institut
cari
nc
ethic
approv
obtain
ucla
field
school
public
health
kinshasa
school
public
health
fourteen
individu
identifi
survivor
ebov
outbreak
yambuku
drc
data
survivor
characterist
present
tabl
eight
particip
male
femal
rang
year
age
year
age
time
infect
six
individu
classifi
confirm
ebov
case
addit
classifi
suspect
case
base
drc
ministri
health
record
obtain
origin
outbreak
investig
ethic
approv
obtain
particip
institut
inform
consent
obtain
particip
local
languag
first
examin
known
ebola
survivor
es
exhibit
immunoreact
ebov
glycoprotein
gp
ebov
nucleoprotein
np
ebov
viral
matrix
protein
year
initi
infect
among
survivor
exhibit
mild
moder
reactiv
ebov
gp
titer
uml
survivor
consid
strongli
reactiv
titer
uml
measur
commerci
avail
adi
gp
elisa
use
serum
dilut
factor
figur
assess
reactiv
np
identifi
survivor
exhibit
strong
immunoreact
titer
uml
survivor
mild
moder
respons
titer
uml
measur
adi
np
elisa
use
serum
dilut
factor
figur
far
fewer
survivor
exhibit
reactiv
individu
consid
immunoreact
figur
establish
studi
cohort
seroposit
ebov
gp
np
next
assess
reactiv
individu
also
capabl
neutral
viru
three
survivor
demonstr
capac
neutral
pseudoviru
use
serum
dilut
factor
use
ebola
vlp
gluc
entri
inhibit
assay
thought
close
mimic
live
ebov
regard
elicit
immunolog
respons
protect
found
survivor
capabl
neutral
one
demonstr
borderlin
capac
neutral
assay
use
serum
dilut
factor
collect
assay
survivor
identifi
retain
neutral
antibodi
figur
establish
subset
survivor
year
initi
infect
show
neutral
capabl
use
pseudotyp
viral
assay
next
sought
test
neutral
capac
use
live
ebov
four
survivor
abl
neutral
live
viru
use
prnt
demonstr
strong
neutral
use
pseudoviru
assay
well
strong
reactiv
antiebov
igg
assay
use
recombin
viral
protein
subject
neutral
ebov
least
use
dilut
complement
protein
inactiv
subject
show
even
stronger
trend
neutral
dilut
dilut
complement
protein
inactiv
despit
inabl
neutral
pseudoviru
prnt
reveal
subject
neutral
live
ebov
least
control
serum
dilut
nonact
compliment
protein
note
howev
neutral
curv
atyp
may
indic
patient
simpli
exhibit
nonspecif
inhibit
toxic
oppos
actual
specif
ebov
neutral
capabl
figur
recent
evd
outbreak
highlight
need
develop
effect
therapeut
vaccin
limit
pathogenesi
viral
spread
current
grow
bodi
evid
offer
hope
find
way
pharmacolog
mimic
boost
natur
resist
individu
appear
toward
ebov
infect
viral
protein
play
key
role
interact
ebov
infect
gp
major
determin
entri
cellular
tropism
import
protein
involv
pathogenesi
primari
target
protect
immun
howev
addit
gp
np
viral
protein
could
individu
synergist
constitut
effect
target
futur
vaccin
therapi
studi
evd
survivor
may
provid
critic
data
inform
strategi
mimick
resili
individu
demonstr
infect
ebov
describ
first
document
live
ebov
neutral
antibodi
persist
within
subset
oldest
known
evd
survivor
year
acut
ebov
infect
addit
data
repres
longest
document
serolog
respons
individu
recombin
ebola
viral
protein
gp
np
live
ebov
longest
durat
antibodi
respons
ebov
infect
measur
year
thu
studi
provid
evid
antibodi
respons
ebov
longliv
extend
significantli
beyond
known
filoviru
infect
previous
document
number
avail
survivor
outbreak
limit
studi
knowledg
examin
longterm
immun
respons
ebov
survivor
time
scale
despit
identifi
level
gp
np
reactiv
studi
cohort
uml
identifi
survivor
retain
immunoreact
find
compar
earlier
studi
serolog
respons
relat
sudan
ebola
viru
ebov
suggest
appear
less
commonli
immunogen
gp
np
gold
standard
live
ebov
neutral
measur
use
prnt
determin
evd
survivor
sampl
could
neutral
actual
viru
vitro
year
infect
four
survivor
antiebola
neutral
titer
also
demonstr
strong
neutral
use
pseudoviru
assay
note
prnt
curv
atyp
rais
possibl
mode
neutral
particular
survivor
may
ebov
specif
rather
nonspecif
inhibit
survivor
neutral
antibodi
react
viral
protein
gp
survivor
consid
strongli
reactiv
survivor
consid
mildli
reactiv
three
survivor
react
strongli
np
one
prnt
neutral
show
respons
recombin
protein
survivor
highest
neutral
capac
prnt
demonstr
reactiv
unlik
studi
shown
human
sera
contain
mannosebind
lectin
enhanc
instanc
neutral
ebov
marv
pseudoviru
appear
compliment
signific
effect
enhanc
antibodymedi
ebov
neutral
capac
work
necessari
accur
assess
best
measur
predict
neutral
variabl
neutral
respons
gp
np
howev
initi
screen
np
gp
reactiv
appear
like
neutral
viru
downstream
applic
given
within
studi
cohort
major
survivor
react
least
mildli
gp
yet
unabl
neutral
may
indic
gp
respons
necessarili
best
indic
downstream
neutral
addit
strongest
prnt
neutral
extrem
low
respons
gp
yet
high
respons
np
howev
also
import
note
protect
antibodi
necessarili
alway
neutral
use
vitro
assay
lead
possibl
vivo
survivor
cohort
may
protect
reinfect
document
case
reinfect
ebov
given
small
sampl
size
abl
find
signific
trend
symptom
report
exposur
rout
demograph
factor
predict
neutral
antibodi
respons
year
postinfect
howev
result
agre
previou
studi
found
known
survivor
harbor
detect
antibodi
viral
protein
full
viru
antigen
interestingli
survivor
whose
sera
demonstr
greatest
abil
neutral
live
viru
healthcar
worker
enrol
studi
indic
type
individu
investig
greater
depth
futur
research
questionnair
data
individu
indic
multipl
exposur
ebola
outbreak
percutan
exposur
well
contact
patient
bodili
fluid
high
level
immunoreact
seen
individu
may
also
result
reexposur
asymptomat
endogen
sylvat
sourc
endem
region
although
mention
human
reinfect
ebov
document
anoth
possibl
relat
virus
may
also
stimul
ebov
humor
immun
enabl
continu
protect
respons
observ
survivor
altern
individu
may
inher
genet
regulatori
differ
enabl
retain
ebov
respons
neutral
capabl
long
initi
infect
wherea
other
lose
abil
rapid
rate
irrespect
mechan
survivor
specif
potent
endur
immunolog
respons
may
guid
benefici
research
prevent
treat
evd
inevit
futur
reoccurr
particip
studi
repres
longterm
survivor
evd
yambuku
outbreak
surviv
long
enough
includ
studi
may
repres
sampl
survivor
first
document
outbreak
howev
individu
known
live
survivor
first
record
ebov
outbreak
histori
repres
uniqu
highli
import
cohort
enabl
opportun
glean
insight
longterm
immun
respons
potent
pathogen
life
expect
popul
among
lowest
world
male
femal
find
survivor
year
one
deadliest
ebola
outbreak
record
present
numer
challeng
yet
better
expect
outcom
age
cohort
apertur
studi
natur
rapidli
close
addit
studi
yambuku
survivor
may
provid
understand
health
challeng
face
survivor
larg
west
african
ebola
outbreak
report
document
antiebola
immun
viral
antigen
year
initi
infect
interestingli
demonstr
subset
survivor
still
capabl
neutral
live
viru
durat
antiebola
humor
respons
fill
knowledg
gap
within
field
provid
evid
infect
ebov
trigger
lifelong
humor
immun
respons
instanc
neutral
live
viru
vitro
